What was the overall market valuation of the US recombinant proteins market in 2024?

The overall market valuation was $554.3 Million in 2024. Read More

What is the projected market valuation for the US recombinant proteins market by 2035?

The projected valuation for 2035 is $1292.7 Million. Read More

What is the expected CAGR for the US recombinant proteins market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 8.0%. Read More

Which product segment had the highest valuation in 2024 within the US recombinant proteins market?

The Antibody segment had the highest valuation at $200.0 Million in 2024. Read More

What is the projected valuation for the Growth Factors segment by 2035?

The projected valuation for the Growth Factors segment is $200.0 Million in 2024 and may increase significantly by 2035. Read More

Which application segment is expected to dominate the US recombinant proteins market?

The Therapeutic Use application segment is expected to dominate, with a valuation of $300.0 Million in 2024. Read More

What was the valuation of the Research Application segment in 2024?

The Research Application segment was valued at $100.0 Million in 2024. Read More

How does the valuation of the Other Types of Products segment compare to others in 2024?

The Other Types of Products segment was valued at $114.3 Million, indicating a competitive position among product segments. Read More

What trends are anticipated for the US recombinant proteins market in the coming years?

Trends suggest a robust growth trajectory, with increasing investments and advancements in biotechnology likely driving market expansion. Read More

US Recombinant Proteins Market

Q: Who are the key players in the US recombinant proteins market?

Key players include Amgen, Genentech, Roche, Bristol-Myers Squibb, Merck KGaA, Novartis, Sanofi, Pfizer, and Eli Lilly. Read More

ID: MRFR/MED/49064-HCR 200 Pages Nidhi Mandole Last Updated: September 17, 2026

US Recombinant Proteins Market Research Report By Product (Hormones, Growth Factors, Antibody, Enzymes, Other Types of Products) and By Application (Research Applications, Therapeutic Use, Biotechnology Industry) - Growth & Industry Forecast 2025 To 2035

US Recombinant Proteins Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.0%

2024 Market Size$ 554.3 Million

2025 Market Size$ 598.65 Million

2035 Market Size$ 1,292.7 Million

Key Players

Amgen

Genentech

Roche

Bristol-Myers Squibb

Merck KGaA

Novartis

Trends

Rising Demand for Therapeutic Proteins
Technological Innovations in Production
Regulatory Developments and Quality Standards

Opportunities

Advancements in Genetic Engineering
Expanding Applications in Diagnostics
Rising Prevalence of Chronic Diseases

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Product (USD Million)
  1. 4.1.1 Hormones
  2. 4.1.2 Growth Factors
  3. 4.1.3 Antibody
  4. 4.1.4 Enzymes
  5. 4.1.5 Other Types of Products
2. 4.2 Industrial Automation & Equipment, BY Application (USD Million)
  1. 4.2.1 Research Application
  2. 4.2.2 Therapeutic Use
  3. 4.2.3 Biotechnology Industry
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Genentech (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck KGaA (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PRODUCT
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PRODUCT, 2024 (% SHARE)
11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PRODUCT, 2024 TO 2035 (USD Million)
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Recombinant Proteins Market Segmentation

US Recombinant Proteins Market By Product (USD Million, 2025-2035)

Hormones
Growth Factors
Antibody
Enzymes
Other Types of Products

US Recombinant Proteins Market By Application (USD Million, 2025-2035)

Research Application
Therapeutic Use
Biotechnology Industry

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”